Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
Systematic review published in Frontiers in medicine (2023)
Abstract
INTRODUCTION: Optimal anticoagulation therapy is essential for the prevention of thrombotic and hemorrhagic complications in pediatric patients supported with extracorporeal membrane oxygenation (ECMO). Recent data have demonstrated bivalirudin has the potential to surpass and replace heparin as the anticoagulant of choice. METHODS: We conducted a systematic review comparing the outcomes of heparin-based versus bivalirudin-based anticoagulation in pediatric patients supported on ECMO to identify the preferred anticoagulant to minimize bleeding events, thrombotic complications, and associated mortality. We referenced the PubMed, Cochrane Library, and Embase databases. These databases were searched from inception through October 2022. Our initial search identified 422 studies. All records were screened by two independent reviewers using the Covidence software for adherence to our inclusion criteria, and seven retrospective cohort studies were identified as appropriate for inclusion. RESULTS: In total, 196 pediatric patients were anticoagulated with heparin and 117 were anticoagulated with bivalirudin while on ECMO. Across the included studies, it was found that for patients treated with bivalirudin, trends were noted toward lower rates of bleeding, transfusion requirements, and thrombosis with no difference in mortality. Overall costs associated with bivalirudin therapy were lower. Time to therapeutic anticoagulation varied between studies though institutions had different anticoagulation targets. CONCLUSION: Bivalirudin may be a safe, cost-effective alternative to heparin in achieving anticoagulation in pediatric ECMO patients. Prospective multicenter studies and randomized control trials with standard anticoagulation targets are needed to accurately compare outcomes associated with heparin versus bivalirudin in pediatric ECMO patients.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
A systematic review of seven retrospective cohort studies covering 196 heparin- and 117 bivalirudin-anticoagulated pediatric ECMO patients found bivalirudin associated with trends toward lower bleeding, transfusion, and thrombosis rates without mortality difference, and lower overall costs.
Why This Matters for Hirudotherapy
This systematic review compared heparin-based versus bivalirudin-based anticoagulation in pediatric ECMO patients, identifying seven retrospective cohort studies (196 heparin patients, 117 bivalirudin patients). The review found trends toward lower bleeding rates, transfusion requirements, thrombosis, and lower overall costs with bivalirudin, with no difference in mortality. The abstract does not mention hirudin, leeches, or any leech-derived product. The authors concluded that bivalirudin may be a safe, cost-effective alternative but prospective multicenter randomized trials with standardized anticoagulation targets are needed. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.
Citation
Reference (Vancouver style)
Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, et al. Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review. Front Med (Lausanne). 2023;10:1137134. doi:10.3389/fmed.2023.1137134. PMID: 36999064
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026